"Weight loss wonder drug" has new efficacy! Novo Nordisk (NVO.US) semaglutide MASH 3rd phase clinical trial reached the primary endpoint

AInvestFriday, Nov 1, 2024 9:10 pm ET

1min read

Novo Nordisk (NVO.US) announced on Friday that its pivotal Phase 3 trial of semaglutide, a weight loss therapy, met its primary endpoint in patients with metabolic dysfunction associated fatty liver disease (MASH) and non-alcoholic steatohepatitis (NASH).

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.